Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Recruiting1
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

recruiting133%
terminated133%
completed133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

DOAC - Dosing Options in AntiCoagulation Prophylaxis

NCT07005024
terminatedphase_3

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

NCT02860130
completed

A Prospective Pharmacodynamic Study of Rivaroxaban

NCT01743898

Clinical Trials (3)

Showing 3 of 3 trials
NCT07005024Phase 3

DOAC - Dosing Options in AntiCoagulation Prophylaxis

Recruiting
NCT02860130Phase 3

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

Terminated
NCT01743898

A Prospective Pharmacodynamic Study of Rivaroxaban

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3